Here at the AACR Annual Meeting 2024, there are over 7000 abstracts, 300 poster presentations, and 50 symposia all about cancer research. A few topics that are currently trending in the conference include cancer vaccines, AI for diagnostics, novel immunotherapies, and antibody-drug conjugates (ADCs) as a new modality.
In March 2024, Cyagen and Biointron officially signed off on their strategic partnership, forging an alliance in antibody drug development. This partnership aims to fully leverage the strengths of Cyagen's HUGO-Ab™ fully humanized mouse antibody discovery platform and Biointron&#
Explore key highlights from Biologics 2024, including advances in ADCs, AI-driven drug discovery, peptide therapeutics, and next-generation biologics innovation.
PepTalk 2024 delivered key insights into antibody development. Explore highlights on formulation, analytics, and modalities that shape the future of biotech innovation.
Our 2023 year‑end networking and game night gathered scientists, partners, and friends to share results, swap ideas, and celebrate antibody discovery that will fuel the next year.
You can also contact us on the Scientist and Science Exchange marketplaces.